Edwards Lifesciences Corp (EW)vsIRIDEX Corporation (IRIX)
EW
Edwards Lifesciences Corp
$85.76
+2.49%
HEALTHCARE · Cap: $49.36B
IRIX
IRIDEX Corporation
$0.86
-1.95%
HEALTHCARE · Cap: $15.51M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 11889% more annual revenue ($6.30B vs $52.58M). EW leads profitability with a 17.4% profit margin vs -6.2%. IRIX appears more attractively valued with a PEG of 0.94. EW earns a higher WallStSmart Score of 61/100 (C+).
EW
Buy61
out of 100
Grade: C+
IRIX
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.2%
Fair Value
$249.70
Current Price
$85.76
$163.94 discount
Margin of Safety
+75.3%
Fair Value
$5.79
Current Price
$0.86
$4.93 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.2%
Safe zone — low bankruptcy risk
16.7% revenue growth
Growing faster than its price suggests
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -126.4% — below average capital efficiency
Revenue declined 0.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin, Altman Z-Score, Revenue Growth. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bull Case : IRIX
The strongest argument for IRIX centers on PEG Ratio. PEG of 0.94 suggests the stock is reasonably priced for its growth.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.3x leaves little room for execution misses.
Bear Case : IRIX
The primary concerns for IRIX are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
EW profiles as a growth stock while IRIX is a turnaround play — different risk/reward profiles.
EW carries more volatility with a beta of 0.85 — expect wider price swings.
EW is growing revenue faster at 16.7% — sustainability is the question.
IRIX generates stronger free cash flow (-1M), providing more financial flexibility.
Bottom Line
EW scores higher overall (61/100 vs 32/100), backed by strong 17.4% margins and 16.7% revenue growth. IRIX offers better value entry with a 75.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →IRIDEX Corporation
HEALTHCARE · MEDICAL DEVICES · USA
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic laser systems, delivery devices, and consumable instrumentation to treat vision-threatening eye diseases in ophthalmology. The company is headquartered in Mountain View, California.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?